March 31st, 2022 (Earnings Report) Dear Reader, We just identified several healthtech stocks that are expected to release earnings this week. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Daré Bioscience
Symbol: DARE
Recent Price: $1.47
Average Analyst Price Target: $4.33 (194.56%)
Market Cap: $112.60M
Last Year's EPS: -$0.16
Consensus EPS Forecast: -$0.15
Expected Earnings Date: Mar 30 2022
Recent Analyst Action: Jason Kolbert, analyst at Dawson James, reiterates coverage on Daré Bioscience (DARE) in the Healthcare sector with a Buy rating and a price target of $ 3 (1 month ago).
TipRanks.com also reports that Daré Bioscience currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $4.33 . The target pricing ranges from a high forecast of $6.00 down to a low forecast of $3.00. Daré Bioscience (DARE)’s last closing price was $1.47 which would put the average price target at 194.56% upside.Here are 3rd party ratings for DARE:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Bottom 36% (162 out of 252)
--------------------------------------------------------------------------
Freeline Therapeutics Holdings
Symbol: FRLN
Recent Price: $1.15
Average Analyst Price Target: $6.00 (421.74%)
Market Cap: $69.92M
Last Year's EPS: -$0.88
Consensus EPS Forecast: -$0.7
Expected Earnings Date: Mar 30 2022
Recent Analyst Action: Dae Gon, analyst at Stifel Nicolaus, reiterates coverage on Freeline Therapeutics Holdings (FRLN) in the Healthcare sector with a Buy rating and a price target of n/a (1 week ago).
TipRanks.com also reports that Freeline Therapeutics Holdings currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $6.00 . The target pricing ranges from a high forecast of $10.00 down to a low forecast of $2.00. Freeline Therapeutics Holdings (FRLN)’s last closing price was $1.15 which would put the average price target at 421.74% upside.Here are 3rd party ratings for FRLN:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Buy, Bottom 36% (162 out of 252)
--------------------------------------------------------------------------
PDS Biotechnology
Symbol: PDSB
Recent Price: $6.29
Average Analyst Price Target: $18.50 (194.12%)
Market Cap: $178.87M
Last Year's EPS: -$0.18
Consensus EPS Forecast: -$0.24
Expected Earnings Date: Mar 30 2022
Recent Analyst Action: Robert LeBoyer, analyst at Noble Financial, reiterates coverage on PDS Biotechnology (PDSB) in the Healthcare sector with a Buy rating and a price target of $ 22 (2 weeks ago).
TipRanks.com also reports that PDS Biotechnology currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $18.50 . The target pricing ranges from a high forecast of $22.00 down to a low forecast of $15.00. PDS Biotechnology (PDSB)’s last closing price was $6.29 which would put the average price target at 194.12% upside.Here are 3rd party ratings for PDSB:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 36% (162 out of 252)
--------------------------------------------------------------------------
Spero Therapeutics
Symbol: SPRO
Recent Price: $8.61
Average Analyst Price Target: $43.50 (405.23%)
Market Cap: $278.31M
Last Year's EPS: -$0.68
Consensus EPS Forecast: -$0.75
Expected Earnings Date: Mar 30 2022
Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on Spero Therapeutics (SPRO) in the Healthcare sector with a Buy rating and a price target of $ 43 (1 week ago).
TipRanks.com also reports that Spero Therapeutics currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $43.50 . The target pricing ranges from a high forecast of $44.00 down to a low forecast of $43.00. Spero Therapeutics (SPRO)’s last closing price was $8.61 which would put the average price target at 405.23% upside.Here are 3rd party ratings for SPRO:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Bottom 36% (162 out of 252)
--------------------------------------------------------------------------
Taysha Gene Therapies
Symbol: TSHA
Recent Price: $6.15
Average Analyst Price Target: $43.38 (605.37%)
Market Cap: $236.61M
Last Year's EPS: -$0.49
Consensus EPS Forecast: -$1.26
Expected Earnings Date: Mar 30 2022
Recent Analyst Action: Jack Allen, analyst at Robert W. Baird, reiterates coverage on Taysha Gene Therapies (TSHA) in the Healthcare sector with a Buy rating and a price target of $ 26 (2 days ago).
TipRanks.com also reports that Taysha Gene Therapies currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $43.38 . The target pricing ranges from a high forecast of $60.00 down to a low forecast of $25.00. Taysha Gene Therapies (TSHA)’s last closing price was $6.15 which would put the average price target at 605.37% upside.Here are 3rd party ratings for TSHA:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 19% (203 out of 252)
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com